COMPASS Pathways plc (CMPS) 株式分析

企業概要

COMPASS Pathways plc is a biotechnology enterprise dedicated to advancing mental health treatments within the United Kingdom and the United States markets. The firm specializes in the development of COMP360, a psilocybin-based therapy currently undergoing Phase III clinical trials for the treatment of treatment-resistant depression, alongside Phase II clinical development efforts. Operating within the Healthcare sector specifically under the Medical Care Facilities industry classification, the company targets a niche with significant unmet medical needs. With a market capitalization of $719.39M and an employee count of 156, the company maintains a relatively lean operational structure typical of pre-commercial biotechnology entities. The market cap figure indicates that the company is valued based on future potential rather than current cash flow generation, while the absence of reported annual revenue highlights its stage in the clinical development lifecycle where capital expenditure on research and development is the primary financial activity.

財務健全性

The company reports Net Income of $-287,862,016 for the trailing twelve months, accompanied by an EBITDA of $-175,074,000, reflecting the heavy costs associated with clinical trials and regulatory approvals. While Revenue for the trailing twelve months is not disclosed in the available data, the substantial gap between the reported net loss and the EBITDA figure reveals a significant burden from non-operating expenses or other comprehensive losses impacting the bottom line. Despite the negative earnings, the company demonstrates financial flexibility with Free Cash Flow standing at $97.14M, which provides a buffer to fund ongoing research programs without immediate reliance on external equity dilution. However, the balance sheet presents a nuanced picture with total Cash reserves of $149.61M offset by total Debt of $35.03M, indicating a net cash position that supports liquidity but requires careful monitoring of burn rates. The margins across the board are reported as 0.0% for Gross Margin, Operating Margin, and Profit Margin, a common characteristic for biotechs in clinical stages where revenue is negligible compared to operational costs. Liquidity analysis shows a Current Ratio of 0.77, suggesting that short-term current liabilities slightly exceed current assets, which warrants attention to working capital management as the company moves toward commercialization. Furthermore, the Return on Equity stands at -565.3% and Return on Assets at -51.7%, metrics that indicate the company is currently destroying value in accounting terms due to high loss accumulation relative to the equity base and asset base.

バリュエーション評価

Valuation metrics for COMPASS Pathways plc are heavily influenced by its lack of profitability, resulting in a Forward P/E of -4.67 and a Trailing P/E (TTM) that is not applicable due to the negative earnings. The negative Forward P/E implies that the market is pricing in a turnaround or significant future earnings generation rather than current operational performance, creating a divergence between historical loss and projected future earnings trajectory. The Price to Book ratio is calculated at -10.15, which indicates a negative book value per share and suggests that the market is not assigning a premium over the book value, but rather pricing the stock based on intangible assets and future optionality. Alternative valuation measures such as the Price to Sales ratio are not applicable given the lack of revenue data, while the EV/EBITDA stands at -3.46, further emphasizing the speculative nature of the valuation driven by potential clinical trial success rather than current cash flows. Price action analysis reveals a 52-Week High of $8.90 and a 52-Week Low of $2.25, providing the trading range within which the current market price fluctuates. The stock exhibits a Beta of 2.02, meaning that the share price is expected to be twice as volatile as the broader market, amplifying both potential gains and losses in response to sector-specific news or macroeconomic shifts.

Growth & Income

Revenue Growth year-over-year and Earnings Growth year-over-year are both listed as not applicable, which prevents a direct comparison of earnings growth versus revenue growth at this stage of development. Since the company does not pay a dividend, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the firm retains all available capital to reinvest into its drug development pipeline rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's lifecycle stage, where capital preservation and funding of Phase III trials are prioritized over income generation for investors. Consequently, the overall growth and income profile is defined entirely by the potential value creation from the successful commercialization of COMP360 and the progression of its clinical program, rather than traditional metrics of revenue expansion or shareholder yield.